Azilect pills 1 mg №30

Packaging

30 pieces

Mechanism of action

Azilect - antiparkinsonic agent - MAO inhibitor. Rasagiline is a selective irreversible inhibitor of monoamine oxidase type B (MAO-B), an enzyme that 80% determines the activity of monoamine oxidase in the brain and dopamine metabolism. It is 30-80 times more active for MAO-B than for another type of this enzyme, MAO-A. As a result of the inhibitory effect of the drug Azilekt on MAO-B in the central nervous system, the level of dopamine increases, the formation of toxic free radicals decreases, the excessive formation of which is observed in patients with Parkinson's disease. Razagilin also has a neuroprotective effect. Unlike non-selective MAO inhibitors, the drug in therapeutic doses does not block the metabolism of biogenic amines ingested with food (for example, tyramine), and therefore does not cause tyramine-related hypertensive syndrome ("cheese effect").

Indications and usage

Azilekt

Monotherapy or combination therapy for Parkinson's disease (with levodopa preparations).

Contraindications

• hypersensitivity to rasagiline or any of the components of the drug;
• concomitant therapy with pethidine or other MAO inhibitors, Fluoxetine and fluvoxamine. The interval between the withdrawal of rasagiline and the start of therapy with these drugs should be at least 14 days;
• moderate or severe liver failure (Child-Pugh);
• combined therapy with decongestants, sympathomimetics (including those containing them), dextromethorphan.
• pheochromocytoma;
• age under 18;
• pregnancy;
• lactation period (risk of inhibition of milk production against the background of inhibition of prolactin formation).

Dosage and administration

Azilect is used orally in a dose of 1 mg once a day both in monotherapy and on the background of the use of levodopa, for a long time. Drug intakeAzilekt does not depend on food intake.

Adverse reactions

These side effects occurred with a frequency of more than 1/100, side effects occurring with a frequency of 1/100 - 1/1000 are indicated as rare.
With monotherapy Azilekt: 
Nervous system: headaches, depression, dizziness, anorexia, convulsions, rarely: violation of cerebral circulation.
From the gastrointestinal tract: loss of appetite, dyspeptic symptoms.
Musculoskeletal system: arthralgia, arthritis, pain in the neck.
From the skin: vesicular globular rash, contact dermatitis; rarely: skin carcinoma.
Cardiovascular: angina, rarely: myocardial infarction.
Other: fippopodobny syndrome, fever, leukopenia, rhinitis, general weakness, conjunctivitis, acute disorders of the urinary system, allergic reactions.
When applied Azilekt together with levodopa:
Nervous system: dyskinesia, muscular dystopia, anorexia, unusual dreams, ataxia, rarely: impaired cerebral circulation.
From the organs of the gastrointestinal tract: constipation, vomiting, abdominal pain, dry mouth.
Musculoskeletal system: arthralgia, pain in the neck, tendosynoviitis.
From the skin: rash, rarely: melanoma of the skin.
Cardiovascular: postural hypotension, rarely: angina.
Other: accidental drops, weight loss, allergic reactions.
There are two reports about the development of rhabdomyolysis and the violation of the secretion of antidiuretic hormone. Both cases were recorded during post-registration studies without placebo control, developed against the background of a fall and subsequent prolonged immobilization. The relationship between these complications and the admission Azilekt impossible to determine.

Application Azilekt in the recommended therapeutic dose, it does not cause "tyramine syndrome" ("cheese effect"), which allows patients to use food containing significant amounts of tyramine (cheese, chocolate, etc.) without any restrictions. Impact study Azilekt to drive a car and control other mechanisms was not conducted.

Drug interactions

Due to the fact that the mechanism of action Azilekt associated with the inhibition of MAO, as in the case of other drugs of a similar mechanism of action, it cannot be administered simultaneously with other inhibitors of this enzyme due to the risk of a hypertensive crisis. Combination use should be avoided. Azilekt with drugs whose mechanism of action includes the inhibition of reverse neuronal seizure of serotonin (fluoxetine, fluvoxamine, etc.), tricyclic and tetracyclic antidepressants, MAO inhibitors, as this may develop a “serotonergic syndrome”, manifested in the confusion of consciousness, hypomaniacal state, motor restlessness, chills, tremor, diarrhea. If necessary, use by patients receiving rasagiline, such drugs - they are used with caution.
Not recommended for combined use. Azilekt with sympathomimetic drugs, including ephedrine, pseudoephedrine, contained in preparations for the treatment of rhinitis or the common cold (decongestants). In addition, the appointment is not recommended Azilekt with the analgesic / antitussive drug dextromethorphan and the combined means containing it. Due to the fact that the cytochrome P450 1A2 isoform of the enzyme (CYP1A2) is involved in the metabolism of rasagiline,active inhibitors of this enzyme (for example, ciprofloxacin) can increase the concentration of the drug in the blood plasma, which determines caution when combining such drugs with rasagiline.
In patients with Parkinson's disease, the use of levodopa preparations does not affect the clearance of rasagiline.

Overdosage

Symptoms of drug overdose Azilekt similar to overdose with non-selective MAO inhibitors (arterial hypertension, postural hypotension, etc.).
Treatment: There is no specific antidote. Gastric lavage, Activated carbon intake, symptomatic therapy.

At a temperature not higher than 25 ° С. Keep Azilekt out of the reach of children.

of the year